Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debashis Sarker

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Clinical Drug Investigation|February 27, 2022
Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular CarcinomaBaek-Yeol Ryoo, Daniel H Palmer, Sook Ryun Park, et al.
Clinical Drug Investigation|August 5, 2021
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular CarcinomaBaek-Yeol Ryoo, Daniel H Palmer, Sook Ryun Park, et al.
Journal of Intellectual & Developmental Disability|January 16, 2025
Preconditions influencing the development of post-secondary training programs in universities for individuals with intellectual disabilitiesDenise De Souza, Zelinna Pablo, Michael Shevlin, et al.
BMC Cancer|January 20, 2025
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2Hemant M Kocher, , , et al.
Advances in Therapy|April 6, 2021
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect ComparisonJörg Trojan, Patrick Mollon, Bruno Daniele, et al.
Journal of Neuroendocrinology|March 12, 2024
Neuroendocrine neoplasms: Consensus on a patient care pathwayJessica Hooper, Nikie Jervis, Lucy Morgan, et al.
Journal of Neuroendocrinology|February 23, 2024
The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumoursDominique S V M Clement, Monique E van Leerdam, Margot E T Tesselaar, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2018
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumorsMary E R O'Brien, Debashis Sarker, Jaishree Bhosle, et al.
Frontiers in Oncology|March 19, 2020
Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS StudySam Sollie, Aida Santaolalla, Dominique S Michaud, et al.
European Journal of Gastroenterology & Hepatology|September 14, 2016
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problemDimitrios C Ziogas, Dionysios Papadatos-Pastos, Kiruthikah Thillai, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Clinical Drug Investigation|February 27, 2022
Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular CarcinomaBaek-Yeol Ryoo, Daniel H Palmer, Sook Ryun Park, et al.
Clinical Drug Investigation|August 5, 2021
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular CarcinomaBaek-Yeol Ryoo, Daniel H Palmer, Sook Ryun Park, et al.
Journal of Intellectual & Developmental Disability|January 16, 2025
Preconditions influencing the development of post-secondary training programs in universities for individuals with intellectual disabilitiesDenise De Souza, Zelinna Pablo, Michael Shevlin, et al.
BMC Cancer|January 20, 2025
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2Hemant M Kocher, , , et al.
Advances in Therapy|April 6, 2021
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect ComparisonJörg Trojan, Patrick Mollon, Bruno Daniele, et al.
Journal of Neuroendocrinology|March 12, 2024
Neuroendocrine neoplasms: Consensus on a patient care pathwayJessica Hooper, Nikie Jervis, Lucy Morgan, et al.
Journal of Neuroendocrinology|February 23, 2024
The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumoursDominique S V M Clement, Monique E van Leerdam, Margot E T Tesselaar, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2018
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumorsMary E R O'Brien, Debashis Sarker, Jaishree Bhosle, et al.
Frontiers in Oncology|March 19, 2020
Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS StudySam Sollie, Aida Santaolalla, Dominique S Michaud, et al.
European Journal of Gastroenterology & Hepatology|September 14, 2016
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problemDimitrios C Ziogas, Dionysios Papadatos-Pastos, Kiruthikah Thillai, et al.
Pageof 8